Your browser is no longer supported. Please, upgrade your browser.
Settings
BIIB Biogen Inc. daily Stock Chart
BIIB [NASD]
Biogen Inc.
IndexS&P 500 P/E17.99 EPS (ttm)17.13 Insider Own0.10% Shs Outstand219.10M Perf Week-2.73%
Market Cap67.52B Forward P/E14.77 EPS next Y20.87 Insider Trans-3.01% Shs Float218.50M Perf Month6.62%
Income3.82B PEG1.89 EPS next Q5.02 Inst Own88.30% Short Float1.16% Perf Quarter8.97%
Sales11.24B P/S6.01 EPS this Y24.00% Inst Trans-0.21% Short Ratio1.20 Perf Half Y18.79%
Book/sh52.05 P/B5.92 EPS next Y3.76% ROA18.50% Target Price340.33 Perf Year1.21%
Cash/sh17.33 P/C17.78 EPS next 5Y9.50% ROE36.60% 52W Range223.02 - 333.65 Perf YTD0.59%
Dividend- P/FCF21.00 EPS past 5Y31.30% ROI23.50% 52W High-7.64% Beta0.89
Dividend %- Quick Ratio2.60 Sales past 5Y17.90% Gross Margin88.20% 52W Low38.18% ATR8.28
Employees7350 Current Ratio3.00 Sales Q/Q11.70% Oper. Margin47.90% RSI (14)58.18 Volatility2.96% 2.66%
OptionableYes Debt/Eq0.57 EPS Q/Q21.60% Profit Margin34.00% Rel Volume0.53 Prev Close306.85
ShortableYes LT Debt/Eq0.57 EarningsJul 21 BMO Payout0.00% Avg Volume2.10M Price308.17
Recom2.10 SMA20-1.56% SMA5011.20% SMA20012.55% Volume1,120,802 Change0.43%
Jun-29-16Initiated Bernstein Outperform
Jun-07-16Downgrade Citigroup Buy → Neutral
Feb-25-16Initiated Citigroup Buy $345
Jan-20-16Initiated Credit Suisse Neutral
Jan-07-16Initiated Standpoint Research Buy $360
Dec-04-15Resumed Wells Fargo Outperform
Oct-22-15Reiterated H.C. Wainwright Buy $380 → $360
Sep-09-15Initiated Jefferies Buy
Sep-01-15Initiated Raymond James Strong Buy $400
Aug-11-15Initiated H.C. Wainwright Buy $380
Jul-27-15Upgrade Bernstein Mkt Perform → Outperform $436 → $385
Jul-27-15Reiterated RBC Capital Mkts Outperform $525 → $450
Jul-27-15Reiterated Argus Buy $450 → $360
Jul-27-15Downgrade Robert W. Baird Outperform → Neutral $480 → $316
Jul-24-15Downgrade BMO Capital Markets Outperform → Market Perform $511 → $360
Jul-22-15Downgrade Piper Jaffray Overweight → Neutral
Jul-14-15Upgrade BofA/Merrill Neutral → Buy
Jun-11-15Reiterated Leerink Partners Outperform $532 → $512
Jun-09-15Initiated Guggenheim Neutral
Apr-27-15Reiterated UBS Neutral $350 → $422
Aug-26-16 10:05AM  What Should We Expect from BioMarins Kuvan in 2016?
Aug-25-16 01:04PM  Whats BioMarins Expected Revenue Growth in 2016 and 2017?
11:04AM  AbbVie Expects to Launch Zinbryta in the US in August
09:30AM  Allergan, Humana, Biogen: Billionaires Favorite Healthcare Stocks For Q3 at Insider Monkey
08:40AM  Short Sellers Increase Bets in Major Biotechs at 24/7 Wall St.
Aug-24-16 02:09PM  Biotech Stock Roundup: Medivation to Pfizer, Clovis Priority Review
Aug-20-16 08:34AM  9 Stocks Smart Investors Put Their Money in Last Quarter
Aug-18-16 09:06AM  Genzyme Continued to Boost Growth for Sanofi in 2Q16
09:04AM  Ozanimod May Prove to Be a Strong Growth Driver for Celgene
Aug-17-16 08:21AM  Better Buy: Amgen Inc. vs. Biogen at Motley Fool
Aug-16-16 03:48PM  Ionis Pharmaceuticals Inc Begins to Shift Focus at Motley Fool
Aug-15-16 07:17PM  Sarah Ketterer Takes 3 Positions in 2nd Quarter
05:00PM  Amid takeover rumors, Biogen gives details on hemophilia spinoff at bizjournals.com
02:44PM  Top 3 Research Reports for August 15, 2016
09:15AM  Post Earnings Coverage as Perrigo Doubles Profit
09:13AM  Allergan to Buy ForSight VISION5, Boost Glaucoma Pipeline
Aug-12-16 06:07PM  Richard Snow Slashed Abercrombie & Fitch Stake in 2nd Quarter
09:30AM  The Zacks Analyst Blog Highlights: Regeneron, BioMarin, AbbVie, Amgen and Biogen
06:30AM  Analysts: Gilead Should Divide Itself and Conquer
Aug-11-16 05:30PM  Biotech Stock Roundup: Earnings in Focus, AbbVie Takes Steps to Block Humira Copycat
12:34PM  ETFs with exposure to Biogen, Inc. : August 11, 2016
12:28PM  Valeant sinks on criminal probe
11:30AM  Heres what we know about Shires cost-cutting plans for the next three years at bizjournals.com
11:16AM  Glaucoma Treatment Maker a $95M "Stepping Stone" for Allergan
08:20AM  Why Jefferies Sees 3 Big Biotechs Having Key Upside Catalysts Coming at 24/7 Wall St.
Aug-10-16 03:49PM  Ionis (IONS) Q2 Loss Narrower than Expected, Issues Outlook
10:49AM  Perrigo (PRGO) Misses Q2 Earnings Estimates, Cuts '16 View
08:50AM  Short Sellers Run for Cover From Major Biotechs at 24/7 Wall St.
Aug-09-16 09:30AM  The Zacks Analyst Blog Highlights: Intel, Align Technology, Qorvo and Biogen
09:26AM  Biogen's hemophilia business spinoff planned for early 2017 at MarketWatch
09:08AM  What Do Analysts Recommend for Regeneron after 2Q16 Earnings?
09:00AM  Biogen Announces Bioverativ as Name of New Hemophilia-Focused Company Business Wire
03:35AM  Biogen, Eisais Alzheimers Drug E2609 to Enter Late-Stage Trial at Bloomberg
03:01AM  Eisai: FDA confirms enough data to move Alzheimer's drug to Phase III studies
12:08AM  [$$] Allergan Revenue Increases, Though Loss Widens at The Wall Street Journal
Aug-08-16 02:26PM  [$$] Allergan Revenue Increases, Though Loss Widens at The Wall Street Journal
09:30AM  4 Nasdaq Stocks to Dazzle as the Index Hits All-Time High
Aug-05-16 12:10PM  Biogen: Not Your Grandmother's M&A Target at Barrons.com
10:10AM  Biogens MS Drugs: Deadly Cash Cows?
09:30AM  Zacks.com featured highlights: AngloGold Ashanti, Biogen, QUALCOMM, Tallgrass Energy GP and Steel Dynamics
07:01AM  Biotech Stock Mailbag: Ionis, Trust Issues and 'Oops! Don't Look at That Slide Deck'
Aug-04-16 03:24PM  An ETF to Track Companies That Invest Toward Their Future
02:15PM  Biogen (BIIB) Stock Slides, Reportedly Not Pursuing Sale
10:40AM  Merrill Lynch Says the Time to Put Money Into Biotech Is Now at 24/7 Wall St.
06:54AM  Will Merck Pay A 29% Premium for Biogen? at Forbes
05:52AM  Biogen not pursuing a sale: source
05:35AM  Sizzling S&P sectors for summer
12:24AM  [$$] Big Pharmas Biogen Dilemma at The Wall Street Journal
Aug-03-16 07:01PM  Cramer: Does It Have to Be All About Oil?
05:16PM  Stocks to Watch Evening Roundup: Surging Insurers, Sarepta Solace, Kate Spade Spanked at Barrons.com
05:06PM  Biogen Tie-Up Would Still Bring Premium, Analysts Say
02:59PM  [$$] Potential Biogen Buyout May Not Roil Quintiles at Barrons.com
02:15PM  Biogen not pursuing a sale - source
01:24PM  Good, bad, ugly: Biogen, Qorvo and more
12:30PM  Time to buy biotech?
12:24PM  Biogen: Allergan or Merck? Neither at Barrons.com
11:57AM  [$$] Big Pharma's Biogen Dilemma at The Wall Street Journal
10:25AM  Biogen: What's in it for Merck? at Barrons.com
10:02AM  Report: Biogen draws takeover interest from Allergan, Merck at bizjournals.com
09:31AM  Deals of the Day: Biogen Draws Takeover Interest, Time Warner Takes Hulu Stake at The Wall Street Journal
09:21AM  Biogen Buyout Could Be a Boon or a Bust at Bloomberg
09:05AM  Top Analyst Upgrades and Downgrades: Biogen, Discovery Communications, Mosaic, Plains All American, Phillips 66, Rubicon Project and More at 24/7 Wall St.
08:59AM  The Market In 5 Minutes: Downtrend Continues
08:54AM  Cramer's stocks to watch: Most calm down seven days ever
08:30AM  Amyris Enters Partnership with Biogen to Develop Alternative Cell Lines Supporting Production of Therapeutics GlobeNewswire
08:07AM  Pro: Biogen did not put 'for sale' sign out
08:01AM  Etsy, EA, and Avis (CAR) Among 5 Stocks Trending Early Wednesday at Insider Monkey
07:14AM  Wall Street under pressure as Dow looks to snap losing streak at CNBC
07:02AM  Pro: Great deal of skepticism on a Biogen deal
07:01AM  Biogen Is a Takeover Target but Don't Ignore the Risks
06:14AM  Biogen up for takeover?
12:37AM  [$$] Biogen Draws Takeover Interest From Rival Drugmakers at The Wall Street Journal
12:36AM  Whats News: Business & Finance at The Wall Street Journal
Aug-02-16 07:29PM  [$$] Rivals Woo Biogen in Search for Growth at The Wall Street Journal +9.37%
06:17PM  Biogen Jumps as Merger Rumors Resurface
05:54PM  Biogen (BIIB) Stock Declines in After-Hours, Allergan Unlikely to Pursue Takeover
05:28PM  Biogen shares soar on reports of possible takeover from Merck, Allergan at CNBC
05:25PM  Allergan unlikely to pursue biogen deal: Source
05:23PM  Big Biotech Buyout Banter Buoys IBB at Barrons.com
05:00PM  Biogen surges on takeover talk. 4 Trades
04:38PM  Biogen Stock Pops As Merck, Allergan Reportedly Probing Buyout
04:34PM  'We Can Get as High as $475: Biogen Soars on Takeover Speculation; What About Celgene, BioMarin? at Barrons.com
04:17PM  Biogen Spikes as Allergan Tie-Up Rumors Flare Up Again
04:10PM  Biogen (BIIB) Stock Surges 8% on Takeover Rumors
04:05PM  Succession by Acquisition - Biogen, Merck, & Allergan
04:02PM  Pisani: Number of headwinds today
03:49PM  Biogen could become the biggest biotech takeover target in years here's why
03:38PM  CNBC's Tirrell Explains Why Biogen (BIIB) Is a Takeover Target
02:59PM  Merck and Allergan have both expressed interest in a Biogen takeover at MarketWatch
02:59PM  Biogen Briefly Halted, Gains 9% on Takeover Speculation at Barrons.com
02:56PM  Biogen (BIIB) Stock Jumps, Receives Takeover Interest from Merck, Allergan
02:53PM  Biogen draws interest from MRK, AGN
02:52PM  The $75 billion biotech giant Biogen is surging on a report of a potential takeover
02:48PM  Biogen Surges on Report of Interest From Merck, Allergan at Bloomberg
11:42AM  Biogen, Inc. :BIIB-US: Earnings Analysis: Q2, 2016 By the Numbers : August 2, 2016
Aug-01-16 07:05PM  Ionis shares leap 30% after a drug trial goes so well, it ends early at Los Angeles Times
07:01PM  Cramer: What Are You Thinking? It Should Be Long Term
06:51PM  Ionis Pharma CEO: Nusinersen an 'enormous commercial opportunity' at CNBC
05:59PM  Final Trades: J.C. Penney, Biogen and more
05:46PM  [$$] Biogen Soars Past $300 Yet Remains Undervalued at Barrons.com
Biogen Inc. discovers, develops, manufactures, and delivers therapies for the treatment of neurodegenerative diseases, hematologic conditions, and autoimmune disorders. It offers TECFIDERA, AVONEX, and PLEGRIDY to treat relapsing forms of multiple sclerosis (MS); TYSABRI to treat relapsing forms of MS and Crohn's disease; and FAMPYRA to improve walking ability for patients with MS. The company also provides ELOCTATE to treat adults and children with hemophilia A for control of bleeding episodes; ALPROLIX to treat adults and children with hemophilia B for control of bleeding episodes; RITUXAN for treating non-Hodgkin's lymphoma, rheumatoid arthritis, and chronic lymphocytic leukemia (CLL), as well as two forms of ANCA-associated vasculitis; GAZYVA for the treatment of patients with previously untreated CLL; and FUMADERM to treat plaque psoriasis. The company's products in Phase III development stage comprise ZINBRYTA, a monoclonal antibody for the treatment of relapsing-remitting MS; Aducanumab for Alzheimer's disease; and ISIS-SMNRx for spinal muscular atrophy. Its Phase II clinical trial products include Anti-LINGO for optic neuritis and MS; Amiselimod for multiple autoimmune indications; BAN2401 and E2609 for Alzheimer's disease; Raxatrigine for trigeminal neuralgia; rAAV-XLRS for X-linked juvenile retinoschisis; and BG00011 for idiopathic pulmonary fibrosis. Its Phase I clinical trial products comprise Dapirolizumab pegol for systemic lupus erythematosus (SLE); ISIS DMPK for myotonic dystrophy; Anti-BDCA2 for SLE; Anti-alpha-synuclein for Parkinson's disease; and BIIB063 for sjogren's syndrome. The company has a strategic research collaboration with Ionis Pharmaceuticals, Inc. It offers products primarily through its own sales force, marketing groups, and third parties worldwide. The company was formerly known as Biogen Idec Inc. and changed its name to Biogen Inc. in March 2015. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SCANGOS GEORGE AChief Executive OfficerJul 21Sale280.0015743,96054,779Jul 22 05:03 PM
Koppel AdamEVP, Strategy and Bus. Dev.Jun 06Sale290.00555160,9502,402Jun 07 04:09 PM
SCANGOS GEORGE AChief Executive OfficerJun 03Sale290.00842244,18054,936Jun 06 08:14 PM
Koppel AdamEVP, Strategy and Bus. Dev.Jun 02Option Exercise0.001,64303,491Jun 06 08:48 PM
SCANGOS GEORGE AChief Executive OfficerJun 01Sale287.97487140,24155,778Jun 02 04:39 PM
SCANGOS GEORGE AChief Executive OfficerMay 31Sale290.003,368976,72056,265Jun 02 04:39 PM
SCANGOS GEORGE AChief Executive OfficerMay 25Sale280.0015743,96059,633May 27 08:59 AM
SCANGOS GEORGE AChief Executive OfficerMay 02Sale274.74487133,79859,790May 04 05:03 PM
Koppel AdamEVP, Strategy and Bus. Dev.Apr 06Sale275.0010228,0501,848Apr 07 05:03 PM
SCANGOS GEORGE AChief Executive OfficerApr 06Sale280.0015743,96060,277Apr 07 05:01 PM
Artavanis-Tsakonas SpyridonEVP, Chief Scientific OfficerApr 02Option Exercise0.0097503,609Apr 05 05:06 PM
SCANGOS GEORGE AChief Executive OfficerApr 01Sale258.83487126,05060,434Apr 05 05:02 PM
Sandrock AlfredEVP CMO Neuro & NeurodegeneratFeb 25Sale261.9018347,9287,990Feb 26 04:08 PM
ALEXANDER SUSAN HEVP, Chief Legal OfficerFeb 23Option Exercise0.00636032,140Feb 25 05:05 PM
Holtzman Steven HEVP Corporate DevelopmentFeb 23Option Exercise0.0057908,599Feb 25 04:59 PM
DiPietro KennethEVP Human ResourcesFeb 23Option Exercise0.0063604,237Feb 25 05:01 PM
Koppel AdamEVP, Strategy and Bus. Dev.Feb 23Option Exercise0.0030101,963Feb 25 05:02 PM
COVINO GREGORY FVP, Chief Accounting OfficerFeb 23Option Exercise0.006602,709Feb 25 05:09 PM
Clancy Paul JExecutive VP and CFOFeb 23Option Exercise0.00579027,143Feb 25 05:13 PM
SCANGOS GEORGE AChief Executive OfficerFeb 23Option Exercise0.002,964062,812Feb 25 04:51 PM
Sandrock AlfredEVP CMO Neuro & NeurodegeneratFeb 17Sale256.16722184,9487,990Feb 19 04:18 PM
SCANGOS GEORGE AChief Executive OfficerFeb 17Sale256.16487124,75059,848Feb 19 04:20 PM
DiPietro KennethEVP Human ResourcesFeb 12Option Exercise0.003,31604,466Feb 17 06:00 PM
Clancy Paul JExecutive VP and CFOFeb 12Option Exercise0.003,859027,768Feb 17 05:53 PM
Artavanis-Tsakonas SpyridonSVP, Chief Scientific OfficerFeb 12Option Exercise0.001,05702,692Feb 17 05:54 PM
SCANGOS GEORGE AChief Executive OfficerFeb 09Option Exercise0.0011,274052,364Feb 10 04:19 PM
Sandrock AlfredEVP CMO Neuro & NeurodegeneratFeb 09Sale246.54852210,0527,740Feb 10 04:17 PM
Sandrock AlfredEVP CMO Neuro & NeurodegeneratFeb 08Option Exercise0.001,27809,018Feb 10 04:17 PM
Cox JohnEVP Pharmaceutical Oper & TechFeb 08Option Exercise0.004,026029,666Feb 09 04:51 PM
Holtzman Steven HEVP Corporate DevelopmentFeb 08Option Exercise0.002,70907,030Feb 09 04:48 PM
DiPietro KennethEVP Human ResourcesFeb 01Option Exercise273.452,466674,3282,466Feb 02 04:05 PM
Sandrock AlfredEVP CMO Neuro & NeurodegeneratDec 04Sale277.00441122,1577,740Dec 07 04:20 PM
Karaboutis AdrianaEVP, Tech. and Bus. SolutionsDec 02Sale289.144813,8797,875Dec 03 04:19 PM
DENNER ALEXANDER JDirectorOct 23Buy276.77100,00027,677,000310,000Oct 26 07:03 PM
DENNER ALEXANDER JDirectorOct 22Buy277.80210,00058,338,000210,000Oct 26 07:03 PM
Karaboutis AdrianaEVP, Tech. and Bus. SolutionsOct 05Sale291.4326978,3958,094Oct 06 04:40 PM
Karaboutis AdrianaEVP, Tech. and Bus. SolutionsOct 02Sale283.38417118,1698,363Oct 05 04:10 PM
Karaboutis AdrianaEVP, Tech. and Bus. SolutionsOct 01Option Exercise0.001,939010,446Oct 05 04:10 PM